| 2025-10-21 |
详情>>
股本变动：
变动后总股本1847.22万股
变动原因 ▼▲
- 原因：
- Common Stock offered 1,460,000 shares by the company
|
| 2025-08-12 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-3.27美元,归母净利润-2947.46万美元,同比去年增长-2.81%
|
| 2025-05-14 |
详情>>
业绩披露：
2025年中报每股收益-2.58美元,归母净利润-2068.48万美元,同比去年增长-16.37%
|
| 2025-04-28 |
股东大会：
将于2025-06-09召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to our Articles of Incorporation to increase the authorized number of shares from 26,000,000 to 260,000,000 and the authorized number of common shares from 16,000,000 to 250,000,000 (the “Authorized Share Increase Proposal”);
2.To approve the adjournment of the Special Meeting, if necessary, to permit further solicitation and vote of proxies, if there are not sufficient votes at the time of the Special Meeting or any adjournment or postponement thereof to approve the Authorized Share Increase Proposal at the Special Meeting (the “Adjournment Proposal”);
3.To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2025-02-14 |
详情>>
业绩披露：
2025年一季报每股收益-1.3美元,归母净利润-976.82万美元,同比去年增长-5.82%
|
| 2025-01-27 |
股东大会：
将于2025-03-10召开股东大会
会议内容 ▼▲
- 1.To elect seven directors to serve until the 2026 Annual Meeting of Stockholders or until their successors are duly elected and qualified;
2.To approve on a non-binding advisory basis our executive compensation;
3.To approve an amendment to our Articles of Incorporation to increase the authorized number of shares from 26,000,000 to 260,000,000 and the authorized number of common shares from 16,000,000 to 250,000,000;
4.To ratify the selection of Wolf & Company, P.C., an independent registered public accounting firm, as the auditor of the Company for the fiscal year ending September 30, 2025;
5.To approve the Adjournment Proposal.
|
| 2024-12-27 |
详情>>
业绩披露：
2024年年报每股收益-5.97美元,归母净利润-4018.62万美元,同比去年增长-19.27%
|
| 2024-11-26 |
复牌提示：
2024-11-26 09:46:59 停牌，复牌日期 2024-11-26 09:51:59
|
| 2024-11-26 |
详情>>
拆分方案：
每25.0000合并分成1.0000股
|
| 2024-08-12 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.17美元,归母净利润-2867.02万美元,同比去年增长-26.87%
|
| 2024-05-14 |
详情>>
业绩披露：
2024年中报每股收益-0.11美元,归母净利润-1777.53万美元,同比去年增长-25.89%
|
| 2024-03-13 |
详情>>
内部人交易：
Holuka Eugene Myron股份增加2415.00股
|
| 2024-02-14 |
详情>>
业绩披露：
2024年一季报每股收益-0.06美元,归母净利润-923.12万美元,同比去年增长-156.88%
|
| 2024-01-26 |
股东大会：
将于2024-03-12召开股东大会
会议内容 ▼▲
- 1.To elect seven directors to serve until the 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified;
2.To ratify the selection of Wolf & Company, P.C., an independent registered public accounting firm, as the auditor of the Company for the year ending September 30, 2024;
3.To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2023-12-29 |
详情>>
业绩披露：
2023年年报每股收益-0.22美元,归母净利润-3369.41万美元,同比去年增长-0.16%
|
| 2023-08-14 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.15美元,归母净利润-2259.9万美元,同比去年增长11.89%
|
| 2023-05-12 |
详情>>
业绩披露：
2023年中报每股收益-0.1美元,归母净利润-1411.97万美元,同比去年增长15.89%
|
| 2022-12-22 |
股东大会：
将于2023-02-07召开股东大会
会议内容 ▼▲
- 1.To elect seven directors to serve until the 2024 Annual Meeting of Stockholders and until their successors are duly elected and qualified;
2.To approve the Citius Pharmaceuticals, Inc. 2023 Omnibus Stock Incentive Plan;
3.To ratify the selection of Wolf & Company, P.C., an independent registered public accounting firm, as the auditor of the Company for the year ending September 30, 2023;
4.To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2021-12-20 |
股东大会：
将于2022-02-08召开股东大会
会议内容 ▼▲
- 1.To elect seven directors to serve until the 2023 Annual Meeting of Stockholders and until their successors are duly elected and qualified;
2.To approve on a non-binding advisory basis our executive compensation;
3.To recommend, on an advisory basis, a three-year frequency with which the Company should conduct future stockholder advisory votes on our executive compensation;
4.To ratify the selection of Wolf & Company, P.C., an independent registered public accounting firm, as the auditor of the Company for the year ending September 30, 2022;
5.To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-12 |
股东大会：
将于2021-05-24召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to our Articles of Incorporation to increase the authorized number of shares from 210,000,000 to 410,000,000 and the authorized number of common shares from 200,000,000 to 400,000,000;
2.To approve an adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal No. 1;
3.To approve the Citius Pharmaceuticals, Inc. 2021 Omnibus Stock Incentive Plan;
4.To transact such other business as may properly come before the Special Meeting or any adjournment thereof.
|
| 2020-12-21 |
股东大会：
将于2021-02-09召开股东大会
会议内容 ▼▲
- 1.To elect seven directors to serve until the 2022 Annual Meeting of Stockholders and until their successors are duly elected and qualified;
2.To ratify the selection of Wolf & Company, P.C., an independent registered public accounting firm, as the auditor of the Company for the year ending September 30, 2021;
3.To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2019-12-20 |
股东大会：
将于2020-02-10召开股东大会
会议内容 ▼▲
- 1.To elect seven directors to serve until the 2021 Annual Meeting of Stockholders and until their successors are duly elected and qualified;
2.To ratify the selection of Wolf & Company, P.C., an independent registered public accounting firm, as the auditor of the Company for the year ending September 30, 2020;
3.To approve the Citius Pharmaceuticals, Inc. 2020 Omnibus Stock Incentive Plan;
4.To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2018-12-20 |
股东大会：
将于2019-02-13召开股东大会
会议内容 ▼▲
- 1.To elect seven directors to serve until the 2020 Annual Meeting of Stockholders and until their successors are duly elected and qualified;
2.To approve on a non-binding advisory basis our executive compensation;
3.To ratify the selection of Wolf & Company, P.C. as the independent registered public accounting firm of the Company for the year ending September 30, 2019;
4.To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2017-12-13 |
股东大会：
将于2018-02-07召开股东大会
会议内容 ▼▲
- 1.To elect seven (7) directors to serve until the 2019 Annual Meeting of Stockholders and until their successors are duly elected and qualified;
2.To ratify the selection of Wolf & Company, P.C. as the independent registered public accounting firm of the Company for the year ending September 30, 2018;
3.To approve the Citius Pharmaceuticals, Inc. 2018 Omnibus Stock Incentive Plan;
4.To transact such other business as may properly come before the meeting or any adjournment thereof.
|